Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 14Temozolomide 10Specimen Handling 10X-Rays 8Radiotherapy 7Biopsy 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6trametinib 4ulixertinib 3olaparib 3larotrectinib 3erdafitinib 3dabrafenib 3Radiotherapy, Intensity-Modulated 3Nivolumab 3tipifarnib 2selpercatinib 2pembrolizumab 2palbociclib 2niraparib 2ivosidenib 2ensartinib 2atezolizumab 2abemaciclib 2Surveys and Questionnaires 2Radiation 2Proton Therapy 2Lomustine 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioma × BID protein, human × Clear all
NCT05561374 2024-11-29

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Oblato, Inc.

Phase 1 Active not recruiting
16 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡